{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:30:39Z","timestamp":1790267439768,"version":"4.1.0"},"reference-count":58,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T00:00:00Z","timestamp":1386547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Substantial success has been achieved in the development and implementation of West Nile (WN) vaccines for horses; however, no human WN vaccines are approved. This review focuses on the construction, pre-clinical and clinical characterization of ChimeriVax-WN02 for humans, a live chimeric vaccine composed of a yellow fever (YF) 17D virus in which the prM-E envelope protein genes are replaced with the corresponding genes of the WN NY99 virus. Pre-clinical studies demonstrated that ChimeriVax-WN02 was significantly less neurovirulent than YF 17D in mice and rhesus and cynomolgus monkeys. The vaccine elicited neutralizing antibody titers after inoculation in hamsters and monkeys and protected immunized animals from lethal challenge including intracerebral inoculation of high dose of WN NY99 virus. Safety, viremia and immunogenicity of ChimeriVax-WN02 were assessed in one phase I study and in two phase II clinical trials. No safety signals were detected in the three clinical trials with no remarkable differences in incidence of adverse events (AEs) between vaccine and placebo recipients. Viremia was transient and the mean viremia levels were low. The vaccine elicited strong and durable neutralizing antibody and cytotoxic T cell responses. WN epidemiology impedes a classical licensure pathway; therefore, innovative licensure strategies should be explored.<\/jats:p>","DOI":"10.3390\/v5123048","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T12:47:59Z","timestamp":1386593279000},"page":"3048-3070","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Preclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against West Nile Virus"],"prefix":"10.3390","volume":"5","author":[{"given":"Gustavo","family":"Dayan","sequence":"first","affiliation":[{"name":"Sanofi Pasteur, 1 Discovery Drive, Swiftwater,, PA 18370, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Pugachev","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, 38 Sidney St, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bevilacqua","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, 1755 Steeles Ave West, Toronto, ON M2R 3T4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lang","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, 1541 Avenue, Marcel M\u00e9rieux, Marcy-l'\u00c9toile 69280, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Monath","sequence":"additional","affiliation":[{"name":"Acambis Inc., 38 Sidney Street, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2013,12,9]]},"reference":[{"key":"ref_1","unstructured":"Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Straus, S.E., Martin, M.A., and Roizman, B. (2007). Virology, Lippincott Williams and Wilkins, Wolters Kluwer. [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1126\/science.286.5448.2333","article-title":"Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States","volume":"286","author":"Lanciotti","year":"1999","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1128\/JVI.01963-10","article-title":"Phylogeography of West Nile virus: From the cradle of evolution in Africa to Eurasia, Australia, and the Americas","volume":"85","author":"May","year":"2011","journal-title":"J. Virol."},{"key":"ref_4","unstructured":"Centers for Disease Control and Prevention West Nile Virus. Final annual maps and data for 1999\u20132012. Available online:http:\/\/www.cdc.gov\/westnile\/statsMaps\/finalMapsData\/index.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0065-3527(03)60003-5","article-title":"Immunobiology of mosquito-borne encephalitic flaviviruses","volume":"60","author":"Mullbacher","year":"2003","journal-title":"Adv. Virus. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3851\/IMP1767","article-title":"Small molecule pan-dengue and West Nile virus NN3 protease inhibitors","volume":"21","author":"Jiao","year":"2011","journal-title":"Antiviruse Chem. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ben-Nathan, D., Gershoni-Yahalom, O., Samina, I., Khinich, Y., Nur, I., Laub, O., Gottreich, A., Simanov, M., Porgador, A., and Rager-Zisman, B. (2009). Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect. Dis., 9.","DOI":"10.1186\/1471-2334-9-18"},{"key":"ref_8","unstructured":"Gnann, J., and Whithley, R. Personal communication."},{"key":"ref_9","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2013). Vaccines, Elsevier Saunders. [6th ed.]."},{"key":"ref_10","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2013). Vaccines, Elsevier Saunders. [6th ed.]."},{"key":"ref_11","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2013). Vaccines, Elsevier Saunders. [6th ed.]."},{"key":"ref_12","first-page":"37","article-title":"West Nile viruses vaccine","volume":"1","author":"Monath","year":"2001","journal-title":"Curr. Drugs Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00249-07","article-title":"Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model","volume":"4","author":"Seino","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_14","first-page":"285","article-title":"Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation","volume":"1","author":"Rice","year":"1989","journal-title":"New Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.1073\/pnas.88.22.10342","article-title":"Construction of intertypic chimeric dengue viruses by substitution of structural protein genes","volume":"88","author":"Bray","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.1073\/pnas.89.21.10532","article-title":"Construction and characterization of chimeric tick-borne encephalitis\/dengue type 4 viruses","volume":"89","author":"Pletnev","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","unstructured":"Levine, M.M., Dougan, G., Good, M.F., Liu, M.A., Nabel, G.J., Nataro, J., and Rappuoli, R. (2010). New Generation Vaccines, Informa Healthcare. [4th ed.]."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4269\/ajtmh.2004.71.639","article-title":"Yellow fever\/St. Louis encephalitis chimeric virus as a diagnostic tool and a candidate vaccine","volume":"71","author":"Pugachev","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax\u2122-West Nile live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1128\/JVI.75.2.934-942.2001","article-title":"Molecular basis for attenuation of neurovirulence of a yellow fever\/Japanese encephalitis (ChimeriVax-JE) viral vaccine","volume":"75","author":"Arroyo","year":"2001","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1471-4914(01)02048-2","article-title":"Yellow fever vector live-virus vaccines: West Nile vaccine development","volume":"7","author":"Arroyo","year":"2001","journal-title":"Trends Molec. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biologicals.2005.03.009","article-title":"Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys","volume":"33","author":"Monath","year":"2005","journal-title":"Biologicals"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3201\/eid0812.020229","article-title":"Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model","volume":"8","author":"Tesh","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II randomized, double-blind, placebo-controlled, multi-center study to investigate the immunogenicity and safety of a West Nile Vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults \u226550 years of age","volume":"30","author":"Dayan","year":"2012","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase II clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/infdis\/jiq074","article-title":"Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination","volume":"203","author":"Smith","year":"2011","journal-title":"Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e27753","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly Subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: A prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS One"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum. Vaccin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4161\/hv.6.12.13057","article-title":"Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine. Randomized, double-blind, 5-year phase II study in healthy adults","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum. Vaccin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents and adults in Mexico city: Randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/517806","article-title":"In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination","volume":"177","author":"Hacker","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, September 2\u20133, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3201\/eid0706.010617","article-title":"Vector competence of selected North American Culex and Coquillettidia mosquitoes for West Nile virus","volume":"7","author":"Sardelis","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4269\/ajtmh.1939.s1-19.19","article-title":"Failure of Aedes aegypti to transmit yellow fever cultured virus (17D)","volume":"19","author":"Whitman","year":"1939","journal-title":"Am. J. Trop. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4269\/ajtmh.2000.62.480","article-title":"Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF\/JE SA14\u201314\u20132), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes","volume":"62","author":"Bhatt","year":"2000","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2915.2003.00438.x","article-title":"Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes","volume":"17","author":"Johnson","year":"2003","journal-title":"Med. Vet. Entomol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4269\/ajtmh.2003.69.78","article-title":"Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus)","volume":"69","author":"Langevin","year":"2003","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/JCM.01775-10","article-title":"Detection of yellow feveryellow fever 17D genome in urine","volume":"49","author":"Domingo","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e40374","DOI":"10.1371\/journal.pone.0040374","article-title":"Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the houston West Nile virus cohort","volume":"7","author":"Nolan","year":"2012","journal-title":"PLoS One"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/infdis\/jiq057","article-title":"West Nile Virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease","volume":"203","author":"Gibney","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1086\/431153","article-title":"Persistent West Nile virus infection in the golden hamster: Studies on Its Mechanism and Possible Implications for Other Flavivirus Infections","volume":"192","author":"Tesh","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/JVI.78.2.1032-1038.2004","article-title":"High fidelity of yellow fever virus RNA polymerase","volume":"78","author":"Pugachev","year":"2004","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1016\/j.vaccine.2004.11.069","article-title":"Recombination and flavivirus vaccines: A commentary","volume":"23","author":"Monath","year":"2005","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(04)16801-3","article-title":"Arguments for live flavivirus vaccines","volume":"364","author":"Messer","year":"2004","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1016\/j.vaccine.2007.07.016","article-title":"Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE)","volume":"25","author":"Pugachev","year":"2007","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/527329","article-title":"Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates","volume":"197","author":"McGee","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/527328","article-title":"Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes","volume":"197","author":"McGee","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e1000171","DOI":"10.1371\/journal.pmed.1000171","article-title":"A prospective nested case-control study of Dengue in infants: Rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model","volume":"6","author":"Libraty","year":"2009","journal-title":"PLoS Med."},{"key":"ref_58","unstructured":"Federal Drug Administration Science Research. Available online:http:\/\/www.fda.gov\/ScienceResearch\/SpecialTopics\/RegulatoryScience\/default.html."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/5\/12\/3048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:51:12Z","timestamp":1760219472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/5\/12\/3048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,9]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["v5123048"],"URL":"https:\/\/doi.org\/10.3390\/v5123048","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,9]]}}}